Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Biotinylated Human Fc gamma RIIIB / CD16b (NA1) Protein, His,Avitag™ (SPR & BLI verified), His Tag, Avitag™, 200µg  

Recombinant Biotinylated Human Fc gamma RIIIB / CD16b (NA1) Protein, His,Avitag™ (SPR & BLI verified), His Tag, Avitag™, 200µg

Recombinant Biotinylated Human CD16b (NA1), SPR & BLI verified, Gly 17 - Ser 200, expressed from human HEK293 cells His,Avitag

Synonym: recombinant, biotinylated, protein Fc gamma RIIIB / CD16b (NA1), FCGR3B, CD16B, FCG3B, FCGR3, FCG3, IGFR3

More details

CDB-H82E4-200

Availability: within 7 days

1 078,00 €

Background
CD16 is a low affinity Fc receptor, and has been identified as Fc receptors FcγRIIIa (CD16a) and FcγRIIIb (CD16b). These receptors bind to the Fc portion of IgG antibodies. CD16 encoded by two different highly homologous genes in a cell type-specific manner.CD16 is found on the surface of natural killer cells, neutrophil polymorphonuclear leukocytes, monocytes and macrophages. CD16B is also kown as FCGR3B and FCG3B, is expressed specifically by polymorphonuclear leukocytes (neutrophils) and stimulated eosinophils. CD16B is the low affinity receptor for the Fc region of immunoglobulins gamma. FCGR3B binds complexed or aggregated IgG and also monomeric IgG. Contrary to III-A, FCG3B is not capable to mediate antibody-dependent cytotoxicity and phagocytosis. CD16B may serve as a trap for immune complexes in the peripheral circulation which does not activate neutrophils.

Source
Recombinant Biotinylated Human CD16b (NA1), His,Avitag (SPR & BLI verified) (CDB-H82E4) is expressed from human HEK293 cells. It contains AA Gly 17 - Ser 200 (Accession # AAA35881.1). The NA1 form of the CD16b differ with the NA2 form of CD16b in AA36, 65, 82, and 106. The NA1 form carries R36, N65, D82, and V106, while the NA2 form carries S36, S65, N82, and I106. Predicted N-terminus: Gly 17

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag.
The protein has a calculated MW of 24.6 kDa. The protein migrates as 38-48 KDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Biotinylation
Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin

Biotin:Protein Ratio
The biotin to protein ratio is 0.5-1 as determined by the HABA assay.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>95% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22µm filtered solution in PBS (pH 7.4) with Trehalose as protectant.

Reconstitution
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the COA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower. Please avoid repeated freeze-thaw cycles.
No activity loss is observed after storage at: 4-8° C for 12 months in lyophilized state; -70° C for 3 months under sterile conditions, after reconstitution.

Bioactivity
Please refer to product data sheet.

Product specific literature

(1) Ravetch J.V., et al., 1989, J. Exp. Med. 170:481-497.
(2) Gessner J.E., et al., 1995, J. Biol. Chem. 270:1350-1361.
(3) Bux J., et al., 1997, Blood 89:1027-1034.